Journal for Policy & Market Research

The global medical equipment sector represents a critical intersection of advanced engineering, clinical necessity, and rigorous regulatory oversight. As the industry enters 2026, it is characterized by a significant transition from traditional hospital-based capital equipment toward decentralized, connected, and personalized care solutions. The global medical devices market, valued at USD 542.21 billion in 2024, is projected to expand to USD 572.31 billion in 2025, eventually reaching a forecasted USD 886.68 billion by 2032.[1] This compound annual growth rate (CAGR) of 6.5% is underpinned by structural shifts in global demographics, particularly the anticipated rise in the population aged 65 and older from 761 million in 2021 to 1.6 billion by 2050.[1, 2] For an entrepreneur or a scaling organization, starting and building a business in this space requires a nuanced understanding of market dynamics, regulatory stratifications, quality management imperatives, and the evolving landscape of hospital procurement.

Macroeconomic Drivers and Therapeutic Growth Sectors

The momentum of the medical equipment industry is fundamentally linked to the increasing prevalence of chronic and acute diseases, which necessitates continuous innovation in diagnostic and surgical technologies. Diabetes, cardiovascular conditions, and orthopedic disorders are primary drivers of demand.[1] For instance, the global prevalence of diabetes, currently affecting approximately 422 million people, has catalyzed a surge in demand for monitoring and management devices.[1] This trend is coupled with a growing emphasis on early diagnosis, supported by national healthcare agencies to reduce the long-term economic burden of untreated chronic conditions.[1, 2]

Market Stratification and Regional Forecasts

The geographical distribution of market value reveals a dominant North American presence, followed closely by Europe and a rapidly accelerating Asia-Pacific region. North America continues to lead the global landscape, accounting for over 40% of total revenue due to its robust research and development ecosystem, high healthcare expenditure, and favorable reimbursement policies.[2] However, the fastest growth is observed in Asia-Pacific, particularly in China and India, where government-led initiatives are expanding healthcare infrastructure and incentivizing the local production of advanced imaging and surgical systems.[1]

Region	2024 Market Size (USD Billion)	2025 Projected Size (USD Billion)	Growth Driver
North America	206.96	218.44*	Infrastructure Investment and Jobs Act; R&D [1, 2]
Europe	141.00*	148.30	EU MDR compliance; Home healthcare pivot [1, 3]
Asia-Pacific	132.00*	143.12	China/India infrastructure; Urbanization [1]
Rest of World	62.25*	62.45*	Emerging healthcare access in LATAM and MEA [1]

*Calculated estimates based on regional share data and 2025 projections.[1, 2]

Therapeutically, the In-vitro Diagnostics (IVD) segment held the largest market share in 2024, a position it is expected to maintain throughout the forecast period.[1] The dominance of IVD is attributed to the high volume of clinical tests performed globally for infectious diseases and the increasing use of diagnostic data to guide precision medicine.[1] Other high-growth areas include orthopedic devices—driven by joint replacement surgeries—and cardiovascular technologies, such as the FARAPULSE Pulsed Field Ablation System and the Assert-IQ insertable cardiac monitor.[1]

Technological Convergence and Digitization

The industry is undergoing a digital revolution characterized by the integration of Artificial Intelligence (AI), machine learning, and advanced robotics. In 2026, AI is no longer a peripheral feature but a core component of diagnostic imaging, where it assists in identifying anomalies with higher precision than traditional methods.[4] Robotics-assisted surgery continues to advance, offering surgeons small-incision precision and reduced recovery times for complex procedures.[4] Furthermore, the wearable medical device market is projected to more than double, reaching USD 66.9 billion by 2030, as patients and providers increasingly rely on real-time data for chronic disease management.[2]

Regulatory Path Selection and Strategic Compliance

Navigating the regulatory landscape is perhaps the most daunting challenge for any new medical equipment business. In the United States, the Food and Drug Administration (FDA) regulates devices based on a risk-tiered classification system: Class I (low risk), Class II (moderate risk), and Class III (high risk).[5, 6] The selection of the regulatory pathway dictates the development timeline, clinical data requirements, and the capital required to reach the market.[7]

The FDA Framework: 510(k), De Novo, and PMA

The 510(k) premarket notification is the most common pathway for Class II devices. It requires the manufacturer to demonstrate “substantial equivalence” to a legally marketed predicate device.[8, 9] This equivalence is defined by comparing the intended use, technological characteristics, and performance data.[8] If a device is novel but presents low-to-moderate risk, the De Novo pathway is utilized to establish a new classification and a potential predicate for future devices.[5, 7] For high-risk, life-sustaining Class III devices, the Premarket Approval (PMA) pathway is required, necessitating exhaustive clinical trials to prove safety and effectiveness.[5, 6]

Submission Type	Risk Profile	Target Review (Days)	Avg. Total Timeline	2025 Standard Fee (USD)	2025 Small Business Fee (USD)
510(k)	Moderate (II)	90	12–24 Months	24,335	6,084
De Novo	Low/Mod Novel	150	18–30 Months	162,235	40,559
PMA	High (III)	180	3–5 Years	540,783	135,196
513(g)	N/A	60	2–3 Months	7,301	3,650

*Timeline and fee data consolidated from.[5, 7]

Developing a clear regulatory strategy during the concept phase is vital. For first-time submissions, many companies benefit from the Q-Submission (Q-Sub) process, which allows for early engagement with the FDA to clarify testing requirements and predicate selection before the formal filing.[5, 8] This proactive approach can mitigate the risk of a Technical Screening Hold or the costly request for additional information that derails 40% of first-time submissions.[7]

The European Divide: EU MDR Challenges

For businesses targeting the European market, the landscape is significantly more complex due to the ongoing implementation of the EU Medical Device Regulation (MDR).[10, 11] Unlike the FDA’s predicate-based 510(k) system, the EU MDR emphasizes a continuous clinical evaluation process for all devices, requiring more stringent clinical evidence even for lower-risk classifications.[11, 12] The “exact equivalence” standard in the EU is a high barrier for new entrants, and a limited capacity of Notified Bodies (NBs) has created significant bottlenecks in certification.[12, 13] By mid-2025, data showed that while over 28,000 MDR applications were filed, only roughly 12,000 certificates had been issued, with 60% of cases taking 13 to 18 months for completion.[13]

Quality Management Systems and Operational Excellence

The transition from a pre-commercial prototype to a commercialized medical device involves a massive increase in quality management requirements. A Quality Management System (QMS) is the operational playbook that ensures devices are designed, manufactured, and supported in compliance with safety standards such as ISO 13485:2016 and the FDA’s Quality System Regulation (QSR).[10, 14, 15]

The Reactive Remediation Burden

A critical insight for startups is the dramatic increase in quality-related labor once a product enters the market. Research indicates that while pre-commercial companies spend an average of 17 hours per month on reactive remediation, this number jumps to 52 hours per month for commercialized companies.[10] This 200% increase is driven by mandated postmarket surveillance, complaint handling, and the need to maintain an audit-ready state.[10] Effective organizations avoid these pitfalls by building a “lean” but robust QMS early, focusing on document control, risk management (ISO 14971), and design history files (DHF).[16, 17]

Implementation Steps for ISO 13485

Achieving ISO 13485 certification is a foundational milestone for building institutional credibility. The process typically involves six to ten structured steps, starting with a comprehensive gap analysis to identify weaknesses in current procedures.[14, 15]

1. Preparation and Gap Analysis: Comparing current quality policies with ISO 13485 requirements and determining applicable clauses for the specific device type.[14, 16]
2. Documentation and SOP Development: Drafting Standard Operating Procedures (SOPs) for core processes, including document control, training, and design reviews.[16, 18]
3. Team Training and QMS Implementation: Ensuring all personnel understand their roles within the quality framework and their responsibility in maintaining compliance.[15, 17]
4. Internal Audits and Management Review: Conducting “dress rehearsal” audits to identify non-conformities before engaging an external certification body.[14, 15, 18]
5. Certification Audits: A two-stage process where a third-party auditor evaluates documentation (Stage 1) and onsite effectiveness (Stage 2).[16, 18]

Manufacturing Strategy and CMO Partnerships

Medical equipment manufacturers increasingly rely on Contract Manufacturing Organizations (CMOs) or Contract Development and Manufacturing Organizations (CDMOs) to scale production without the massive capital expenditure required for in-house facilities.[19, 20] However, the OEM (Original Equipment Manufacturer) remains legally responsible for the device’s quality, necessitating rigorous supplier oversight.[17, 19]

Selecting the Right Manufacturing Partner

When evaluating a CMO, the technical capabilities must align with the device’s specific needs, such as precision machining, injection molding, or cleanroom assembly.[21, 22] Experience in the medical industry is non-negotiable; general manufacturers may lack the understanding of lot traceability and regulatory mandates required for medical devices.[20, 23]

Selection Criteria	Key Considerations	Risk Factor
Technical Expertise	Experience with specific materials (e.g., medical resins, biocompatible metals).	Incompatibility can lead to device failure.[21, 24]
Scalability	Ability to grow production volumes if market demand surges.	Switching CMOs mid-growth can disrupt sales for months.[22, 23]
Quality Compliance	Adherence to 21 CFR 820 and ISO 13485; history of successful FDA audits.	Poor quality control results in expensive recalls.[20, 24]
Supply Chain Resilience	Strong relationships with raw material vendors to prevent bottlenecks.	COVID-19 exposed vulnerabilities in overseas sourcing.[2, 23]

Sterilization Modalities and Material Science

For sterile devices, the method of sterilization is a critical design input. Ethylene Oxide (EtO) remains the industry standard for complex, heat-sensitive instruments with embedded electronics, as it penetrates effectively without damaging delicate materials.[25, 26, 27] However, EtO requires extensive aeration (8–12 hours mechanically or 7 days passively) to remove toxic residues.[26, 27] Gamma irradiation offers faster turnaround times and deep penetration for bulk-packaged items but can degrade certain polymers and alter material micro-hardness, which is measured in H=52.5432 in specific polymer studies.[26, 28] Newer methods like Vaporized Hydrogen Peroxide (VHP) are gaining traction, having been designated an established Category A method by the FDA in 2024 due to their low environmental impact and lack of toxic residue.[29]

Financial Architecture: IP Strategy and Capitalization

Building a medical equipment business is capital-intensive, with long timelines to revenue. Successful firms utilize a tiered funding strategy that combines non-dilutive government grants with venture capital and strategic partnerships.[30, 31]

Non-Dilutive Funding: SBIR and STTR

The U.S. Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide essential seed capital across three phases. Phase I awards up to USD 275,000 for proof-of-concept work, while Phase II can provide up to USD 1.8 million for technical development.[32, 33] These programs are non-dilutive, meaning the founders retain full equity, which is highly attractive to subsequent venture investors.[32] Agencies like the NIH and DoD also offer specialized grants for technologies targeting military medicine or public health crises like the opioid epidemic.[30, 34]

Intellectual Property as a Value Driver

For an early-stage company, the IP portfolio is the primary asset reviewed during due diligence. A prudent strategy involves a blended approach of patents, trademarks, and trade secrets.[35] Provisional patent applications are often used to secure a priority date at minimal cost, allowing the company 12 months to refine the design before filing a non-provisional application.[35, 36] For global protection, filing under the Patent Cooperation Treaty (PCT) allows a company to postpone country-specific costs for up to 30 months while pursuing FDA or CE marking.[35, 36] Importantly, companies must conduct Freedom-to-Operate (FTO) analysis early to ensure they are not infringing on existing rights in “crowded” therapeutic fields.[35, 37]

Commercialization and the Hospital Procurement Cycle

The “point of sale” in modern healthcare has shifted from individual clinicians to multidisciplinary committees. Achieving market traction requires navigating the complex relationship between Group Purchasing Organizations (GPOs), Integrated Delivery Networks (IDNs), and Value Analysis Committees (VACs).[38, 39]

The Role of the Value Analysis Committee (VAC)

A VAC is the formal gatekeeper for any new product entering a hospital system. They evaluate technologies based on three core pillars: clinical proof, financial ROI, and operational fit.[38] Clinical proof must include peer-reviewed studies or randomized controlled trials; anecdotes from a “champion” surgeon are rarely sufficient in 2025.[38, 40] Financial ROI analysis must demonstrate total cost of ownership, including how the device might reduce readmission penalties or improve staff efficiency.[38, 39, 41] Finally, the operational fit assessment ensures that the device integrates with existing Electronic Health Records (EHR) and IT infrastructures, often requiring HL7/FHIR or cybersecurity certifications.[38]

Leveraging GPOs and Sales Strategies

GPOs act as intermediaries that negotiate contracts for thousands of hospitals, providing vendors with access to high-volume purchasing.[42, 43] For a new entrant, catching the “award cycle” for a GPO contract is critical. Sales teams must track the expiration of existing GPO-provider agreements to time their outreach when hospitals are most open to change.[44] Furthermore, participating in “Reverse Expos,” where manufacturers walk the floor to meet distributor and GPO leaders, provides a unique opportunity to build the visibility needed for enterprise-level deals.[45]

Trade Show / Event	Date	Focus Area	Significance for Startups
HIMSS26	Mar 9-12, 2026	Health IT & Digital Health	Core for AI and connected care platforms.[46]
ViVE 2026	Feb 22-25, 2026	Digital Health Executive	Focuses on C-suite networking and AI partnerships.[47]
MD&M East	May 19-20, 2027	Design & Manufacturing	Critical for finding CMOs and component vendors.[48]
AdvaMed MedTech	Oct 18-21, 2026	Regulatory & Commercial	The premier event for regulatory news and M&A.[49]
MEDICA 2025	Nov 17-20, 2025	Global B2B Trade	The largest European forum for imaging and diagnostics.[50]

Risk Mitigation and Lifecycle Management

Building a successful medical equipment business also requires a robust defense against the inherent risks of product liability and recalls. In 2023, the U.S. medical device industry saw 975 recalls, highlighting the importance of prevention and insurance.[51]

The Pyramid Defense Strategy

A “pyramid defense” approach to risk management starts with a foundation of rigorous testing and quality control.[52] This is supported by clear labeling, instructions for use (IFU), and a proactive system for analyzing customer feedback to catch potential defects before they escalate.[52, 53] Insurance plays a vital role in this hierarchy; while Product Liability Insurance protects against lawsuits related to injuries, Product Recall Insurance is necessary to cover the logistics of removing and disposing of defective products.[53, 54] Small manufacturers must be aware that a single recall can exceed the limits of standard liability policies, making a dedicated recall rider essential for financial sustainability.[54]

Economic Uncertainty and Agility

The economic climate in 2026 remains cautious. Surveys show that 46% of large medical device companies have implemented hiring freezes, and many are delaying new product development due to uncertainty.[10] For a startup, this “operational drag” means that fundraising rounds may take longer and procurement cycles at hospitals may extend to 6–12 months.[10, 38] Maintaining agility—by utilizing fractional leadership, outsourcing to CMOs, and focusing on high-ROI therapeutic niches—is the key to surviving these headwinds.[7, 38]

Conclusions and Strategic Recommendations

Starting and building a business in medical equipment in 2026 is a task of extreme complexity that requires a synthesis of clinical innovation and regulatory precision. The convergence of AI, robotics, and home healthcare is creating massive opportunities for those who can prove value to the Value Analysis Committees. The path forward demands that founders:

• Prioritize a regulatory-first design approach to avoid the USD 500k+ mistakes that derail 40% of first-time submissions.[7]
• Embed a culture of quality early to mitigate the “reactive remediation” jump from 17 to 52 hours per month once a product is launched.[10]
• Focus on the “Three Pillars” of VAC approval—Clinical, Financial, and Operational—to ensure that hospital systems view the device as a “must-have” rather than a disruptive cost.[38]
• Secure non-dilutive capital through SBIR/STTR programs to extend runways and validate technology before seeking major venture rounds.[30, 32]

By systematically addressing these technical, regulatory, and commercial hurdles, medical equipment companies can successfully navigate the journey from concept to a sustainable, patient-centric enterprise.

——————————————————————————–

1. Medical Devices Market Size, Share, Global Growth Report 2032, https://www.fortunebusinessinsights.com/industry-reports/medical-devices-market-100085
2. Medical Device Market Growth Outlook: 2025–2030, https://www.medicalmicromolding.com/medical-device-market-growth-outlook-2025-2030/
3. European Medical Technology Distribution – An … – Roland Berger, https://www.rolandberger.com/publications/publication_pdf/23_8_002_GB_15_European_MedTech_Distributors-Final.pdf?v=829543
4. Medical Device Industry Trends to Look Forward To in 2025 – Medical Sales College, https://medicalsalescollege.com/blog/medical-device-industry-trends/
5. FDA Pathways Explained: 510(k), De Novo & PMA | Educo, https://educolifesciences.com/choosing-the-right-fda-submission-pathway-for-your-medical-device/
6. How to Study and Market Your Device | FDA, https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/how-study-and-market-your-device
7. How to Build a Medical Device Regulatory Strategy: Complete Guide, https://www.complizen.ai/post/how-to-build-a-medical-device-regulatory-strategy-complete-guide
8. Tips for Preparing Successful FDA 510(k) Submissions – ProPharma Group, https://www.propharmagroup.com/thought-leadership/preparing-successful-fda-510k-submission-tips
9. The Ultimate Guide to Medical Devices Submission Pathways – RegASK, https://regask.com/medical-device-submission-pathways/
10. 2025 Medical Device Industry Report: Quality Challenges …, https://www.greenlight.guru/blog/2025-medical-device-industry-report
11. EU MDR vs FDA: 2025 US-EU Medical Device Regulatory Comparison Guide – Complizen, https://www.complizen.ai/post/eu-mdr-vs-fda-complete-regulatory-comparison-guide-2025
12. Webinar: From USA to Europe – Accelerating Your Path to the Medical Device Market, https://mantrasystems.com/articles/from-usa-fda-to-europe-mdr-accelerating-your-path-to-the-medical-device-market-webinar
13. The 2025 MedTech Regulatory Divide: A Strategic Analysis of the US and EU Innovation Landscapes | HTEC, https://htec.com/insights/a-strategic-analysis-of-the-2025-us-eu-medtech-regulatory-divide/
14. How to Get ISO 13485 Certification – Smithers, https://www.smithers.com/resources/2023/july/how-to-get-iso-13485-certification
15. ISO 13485 Certification | A Practical Guide for Medical Devices, https://jjccgroup.org/iso-13485-certification-process/
16. ISO 13485 Implementation for Medical Device Companies: Step-by-Step Guide – Orangesoft, https://orangesoft.co/blog/iso-13485-standard
17. ISO 13485 for Biotech Startups | Key Steps Before Scaling Safely, https://www.americanglobal.org/news/iso-13485-for-biotech-startups-what-you-need-to-know-before-scaling/
18. ISO 13485 Certification: A Guide for IVD Startups – What’s new at Medix Biochemica, https://articles.medixbiochemica.com/iso-13485-certification-a-guide-for-ivd-startups
19. How the Medical Device Industry Works | Umbrex, https://umbrex.com/resources/how-industries-work/healthcare-and-life-sciences/how-the-medical-device-industry-works/
20. What OEMs Need In A Contract Manufacturer: A 10-Point Checklist – GMI Solutions, https://www.gmisolutions.com/blog/what-oems-need-in-a-contract-manufacturer
21. How to Select a Contract Manufacturer: a 9-Point Checklist – FORGE, https://forgeimpact.org/how-to-select-a-contract-manufacturer-a-9-point-checklist/
22. A Checklist: Top 10 Considerations in Choosing a Medical Device Contract Manufacturer, https://www.mpo-mag.com/exclusives/a-checklist-top-10-considerations-in-choosing-a-medical-device-contract-manufacturer/
23. How to Choose the Right Medical Device Manufacturer – Crescent Industries, https://www.crescentind.com/blog/6-factors-for-choosing-a-medical-device-contract-manufacturer
24. Innovator Checklist for Finding Contract … – NIH SEED Office, https://seed.nih.gov/sites/default/files/2023-12/Innovator-Checklist-for-Finding-Contract-Manufacturing-Organization.pdf
25. ETO vs. Irradiation, Autoclave & Emerging Sterilization Methods – PiSA USA, https://www.pisa-usa.com/blog/eto-vs-irradiation-autoclave-and-emerging-sterilization-methods-choosing-the-right-approach-for-your-medical-device
26. Ethylene Oxide Sterilization vs Gamma: What You Need to Know? – Ebeam Machine, https://ebeammachine.com/ethylene-oxide-sterilization-vs-gamma-what-you-need-to-know/
27. Medical Device Sterilization: Methods Explained, Compared & Contrasted – ES Systems – Pressure & Gas Flow Sensor Solutions, https://esenssys.com/news/methods-of-medical-sterilization/
28. Medical Device Sterilization: How To Choose the Right Method – Pathway Medtech, https://pathwaymedtech.com/medical-device-sterilization-how-to-choose-the-right-method/
29. Medical Sterilization and Modern Technologies: A Comprehensive Review of Current Methods and Emerging Innovations, https://diabeticstudies.org/index.php/RDS/article/download/1257/1104/2888
30. Leveraging Government and Industry Grants for Medical Technology Development, https://www.fusiontaxes.com/thought-leadership/blog/leveraging-grants-for-medical-development/
31. Funding for Medical Device Startups: What You Need to Know – Xeraya Capital, https://xeraya.com/medical-device-startups-funding-guide/
32. SBIR.gov, https://www.sbir.gov/
33. Top 12 Health Tech Grants and Funding Resources for U.S. Healthcare Startups, https://orangesoft.co/blog/grant-resources-for-health-tech-startups
34. Activities to Support Medical Device Innovators – FDA, https://www.fda.gov/about-fda/cdrh-innovation/activities-support-medical-device-innovators
35. Intellectual Property Strategy for the Early Stage Medical Device …, https://pressbooks.umn.edu/mdih/chapter/intellectual-property-strategy-for-the-early-stage-medical-device-business/
36. Patent Strategies for Medical Device Companies: Maximizing Innovation and Protection, https://www.mlo-ip.com/blog/patent-strategies-for-medical-device-companies-maximizing-innovation-and-protection
37. Top 5 tips on intellectual property protection for medical devices – Gateley, https://gateleyplc.com/insight/article/top-5-tips-on-intellectual-property-protection-for-medical-devices/
38. How to Get Through a Hospital Value Analysis Committee (Without …, https://accretiveedge.com/articles/hospital-value-analysis-committee-guide/
39. Hospital Procurement: What You Need To Know – H1, https://h1.co/blog/hospital-procurement-what-you-need-to-know/
40. Understanding the Steps in the Hospital Value Analysis Process – MedicalConstructionData, https://www.medicalconstructiondata.com/Content/pdf/MedicalBlog/Understanding%20the%20Steps%20in%20the%20Hospital%20Value%20Analysis%20Process%2005-01-17%20Final.pdf
41. Hospital Value Committees: The Role of the Surgeon in New Technology Adoption – Stanford Medicine, https://med.stanford.edu/pedsortho/education/sports0/_jcr_content/main/panel_builder/panel_0/accordion/accordion_content10/download_853747295/file.res/Hospital%20Value%20Committess-%20Role%20of%20the%20Surgeon%20in%20New%20Technology.pdf
42. McKesson Business Solutions & GPO Strategies, https://www.mckesson.com/business-solutions/our-businesses/gpo-strategies/
43. The strategic advantage of GPOs for medical practices to navigate the age of inflation, https://www.mgma.com/mgma-stat/the-strategic-advantage-of-gpos-for-medical-practices-to-navigate-the-age-of-inflation
44. Scratching the 3-year itch: Why sales should leverage shifting GPO-provider relationships – Definitive Healthcare, https://www.definitivehc.com/blog/sales-leverage-shifting-gpo-provider-relationships
45. Reverse Expo – Health Industry Distributors Association, https://www.hida.org/streamlining-healthcare/streamlining-healthcare/expos/reverse.aspx
46. HIMSS Global Health Conference & Exhibition: Home, https://www.himssconference.com/
47. Top 21 Healthcare Conferences To Attend in 2026 for Digital Health, https://openloophealth.com/blog/top-21-healthcare-conferences-to-attend-in-2026-for-digital-health
48. Trade Fairs in U.S.A.(Medical Care, Health) | Online Trade Fair Database (J-messe) – JETRO, https://www.jetro.go.jp/en/database/j-messe/country/n_america/us/medical/
49. Top medtech conferences in 2026, https://www.medtechdive.com/news/top-medtech-conferences-2026/761495/
50. Top European Medical Device Trade Shows 2025–2026 – Masson International, https://www.massoninternational.com/blog/european-medical-device-trade-shows
51. Product Recall + Contamination Insurance: What Your Clients Need to Know – CRC Group, https://www.crcgroup.com/Tools-and-Intel/post/product-recall-contamination-insurance-what-your-clients-need-to-know
52. What Are the Best Strategies for Managing Product Liability Risks?, https://bdi-insurance.com/blog/product-liability-risk-management-strategies/
53. Product Recall Insurance Coverage | Insureon, https://www.insureon.com/small-business-insurance/product-liability/product-recall
54. Product Liability & Recall | Insurance Broking & Risk Management …, https://www.marsh.com/en/services/product-liability.html